Introduction to RVO-related Macular Edema

Managing RVO-related macular edema effectively is critical because it remains the leading cause of vision loss in patients with retinal vein occlusion. Recent scientific advancements in retinal imaging and pharmacotherapy have revolutionized how clinicians approach this condition. Specifically, the recognition of vascular endothelial growth factor (VEGF) as a primary pathogenic driver has moved anti-VEGF agents to the forefront of clinical practice. Today, these agents serve as the gold standard for treatment in India and globally.

The Evolving Landscape of Anti-VEGF Therapy

Current management protocols prioritize intravitreal anti-VEGF therapy due to robust evidence from randomized controlled trials. These medications successfully reduce fluid accumulation and improve visual acuity in most patients. Furthermore, the introduction of Indian biosimilars like Razumab and Bevatas has significantly enhanced treatment accessibility. These affordable alternatives maintain similar efficacy and safety profiles compared to innovator molecules. Consequently, they help bridge the gap in resource-limited settings where the cost of repeated injections often leads to patient drop-outs.

Role of Diagnostics and Alternative Therapies

Optical coherence tomography (OCT) continues to be the cornerstone of diagnosis and long-term monitoring. It provides precise measurements of central retinal thickness, allowing physicians to tailor treatment intervals. Additionally, clinicians utilize fluorescein angiography to assess retinal perfusion and identify ischemic zones. While anti-VEGF is the primary choice, intravitreal corticosteroids play a vital selective role. Specifically, doctors reserve steroids for patients with suboptimal responses to anti-VEGF agents or those with contraindications, such as recent cardiovascular events.

Future Directions for RVO-related Macular Edema

The future of RVO-related macular edema management aims to improve treatment durability and reduce the injection burden. New bispecific antibodies like Faricimab target both VEGF and Ang-2, potentially offering longer intervals between doses. Moreover, researchers are investigating long-acting delivery systems and gene therapies to provide sustained drug release. These innovations promise a paradigm shift from reactive treatment to more durable, proactive management strategies.

Frequently Asked Questions

What is the first-line treatment for RVO-related macular edema?

Intravitreal anti-VEGF agents are the primary first-line treatment. They effectively reduce macular thickness and improve vision with a favorable safety profile.

How do biosimilars impact treatment in India?

Biosimilars provide cost-effective alternatives to expensive innovator drugs, making long-term treatment more sustainable and accessible for many Indian patients.

When is laser therapy used in RVO management?

The role of laser photocoagulation is now limited. It is generally reserved for neovascular complications rather than serving as a primary treatment for macular edema.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Temkar S et al. Retinal vein occlusion-related macular edema: An updated review of current evidence and future directions. Indian J Ophthalmol. 2026 May 01. doi: 10.4103/IJO.IJO_3361_25. PMID: 42054088.

2. Chakraborty D, Sheth JU. Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Retinal Vein Occlusion (BIOS-RVO Study). Clin Ophthalmol. 2024;18:2865-2871.

3. Popovic MM, Ip MS. Novel advances and emerging therapies for RVO. Retina Specialist. 2024 Dec 23.